Sam Brusco, Associate Editor12.06.23
Medtronic has received CE mark approval for its next-gen, rechargeable Percept RC neurostimulator for deep brain stimulation (DBS) to treat symptoms related to Parkinson’s disease, essential tremor, primary dystonia, and epilepsy.
The company said that Percept RC is the smallest, thinnest device on the market and the only rechargeable DBS system with BrainSense sensing tech to be launched in the EU.
BrainSense helps track brain signals and correlate them with symptoms of side-effects associated with their disease or the medications that treat it. Therapy can be tuned to evolving needs based on that information, instead of clinical assessments and patient-reported data alone, Medtronic said.
"This development represents a critical step in our journey to transform Brain Modulation through sensing-enabled DBS," said Amaza Reitmeier, VP and GP for Medtronic Brain Modulation. "We are excited about the potential of Percept RC to provide a comfortable, personalized DBS therapy to those living with Parkinson’s disease, essential tremor and primary dystonia. Percept RC is also the only rechargeable neurostimulator approved to serve patients with epilepsy.”
Medtronic’s Overdrive battery allows therapy to be adjusted without affecting battery capacity. The company said with weekly charging, Percept RC has more than 99% capacity at 15 years, and patients can charge, under normal conditions (from 10-90% full) in under an hour.
Percept DBS therapy also hold MR-conditional labeling for 1.5T and 3T full-body MRI scans without having to turn off therapy. It will become available in Western Europe in mid-December. It’s also available in Japan under review by the FDA.
The first generation Percept RC device was launched in 2020.
The company said that Percept RC is the smallest, thinnest device on the market and the only rechargeable DBS system with BrainSense sensing tech to be launched in the EU.
BrainSense helps track brain signals and correlate them with symptoms of side-effects associated with their disease or the medications that treat it. Therapy can be tuned to evolving needs based on that information, instead of clinical assessments and patient-reported data alone, Medtronic said.
"This development represents a critical step in our journey to transform Brain Modulation through sensing-enabled DBS," said Amaza Reitmeier, VP and GP for Medtronic Brain Modulation. "We are excited about the potential of Percept RC to provide a comfortable, personalized DBS therapy to those living with Parkinson’s disease, essential tremor and primary dystonia. Percept RC is also the only rechargeable neurostimulator approved to serve patients with epilepsy.”
Medtronic’s Overdrive battery allows therapy to be adjusted without affecting battery capacity. The company said with weekly charging, Percept RC has more than 99% capacity at 15 years, and patients can charge, under normal conditions (from 10-90% full) in under an hour.
Percept DBS therapy also hold MR-conditional labeling for 1.5T and 3T full-body MRI scans without having to turn off therapy. It will become available in Western Europe in mid-December. It’s also available in Japan under review by the FDA.
The first generation Percept RC device was launched in 2020.